Plasma levels of cyclic GMP, immune parameters and depressive status during interferon therapy

Neuropsychobiology

Volumn 35, Issue 3, 1997, Pages 128-131

  Kagaya, Ariyuki ^a   Uchitomi, Yosuke ^b   Takezaki, Eiichi ^c   Fukue, Mayumi ^a   Tsukano, Ken ^a   Kugaya, Akira ^a   Minagawa, Hideaki ^a   Takebayashi, Minoru ^a   Zensho, Hidenobu ^a   Oyamada, Takahiro ^a   Yamawaki, Shigeto ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KURE MEDICAL CENTER AND CHUGOKU CANCER CENTER   (Japan)

Author keywords

Cyclic GMP; Depression; Interferon; Soluble interleukin 2 receptor

Indexed keywords

CYCLIC GMP; INTERFERON; INTERLEUKIN 2 RECEPTOR;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; HEPATITIS C; HUMAN; IMMUNOREACTIVITY; JAPAN; MALE; MOOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; CYCLIC GMP; DEPRESSIVE DISORDER; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERONS; JAPAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 8244248453     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000119333     Document Type: Article

References (24)

1. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner L. Goodman Z, Banks SM, Hoofnagle JH: Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, pla-cebo-controlled trial. N Engl J Med 1989:321: 1506-1510.
2. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DB, Rustgi V, Jones EA: Psychiatric complications of long-term interferon alpha therapy. Arch Intern Med 1987; 147:1577-1580.
3. McDonald EM, Mann AH, Thomas HC: Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant α-interferon in hepatitis-B carriers. Lancet 1987; 21:1175-1178.
4. Maes M, Meitzer HY, Stevens W, Cosyns P, Blockx P: Multiple reciprocal relationships between in vivo cellular immunity and hypothalamic-pituitary-adrenal axis in depression. Psychol Med 1994;24:167-177.
5. Simmons ML, Murphy S: Cytokines regulate L-arginine-dependent cyclic GMP production in rat glial cells. Eur J Ncurosci 1993:5:825-831.
6. Feinstem DL, Galea E, Roberts S, Berquist H, Wang H, Reis DJ: Induction of nitric oxide synthase in rat C6 glioma cells. J Neurochcm 1994;62:315-321.
7. Okada F, Honma M, Ui M: Plasma cyclic nucleotide responses to psychological stress in normal and neurotic subjects. J Clin Endocrinol Metab 1983;57:78-81.
8. Makris M, Preston FE, Ralph S: Increased soluble IL-2 receptor levels in HCV-infected haemophiliacs: A possible indicator of liver disease severity. Br J Haematol 1994;87:419-421.
9. Kuzel TM, Gilyon K, Springer E, Variakojis D, Kaul K, Bunn PA Jr., Evans L, Roenigk HH Jr. Rosen ST: Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990:82: 203-207.
10. Meyers CA, Scheibcl RS, Forman AD: Persistent neurotoxicity of systemically administered intcrferon-alpha. Neurology 1991;41:672-676.
11. Thomas MA, Ibanez H: Interferon alpha-2a in the treatment of subfoveal choroidal neovascularization. Am J Ophthalmol 1993; 115:563-568.
12. Arthur CK, Ma DDF: Combined interferon alpha-2a and cytosine arabinosidc as first-line treatment for chronic myeloid leukemia. Acta Haematol 1993:89:15-21.
13. Lewis ML, Davis J, Chang E: Interferon alpha-2a in the treatment of exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1993;231:615-618.
14. Schnitman SM, Vogel S, Baseler M, Lane HC, Davey RT Jr: A phase I study on interferon-α2b in combination with interteukin-2 in patients with human immunodeficiency virus infection. J Infect Dis 1994;169:981-989.
15. Blalock EJ, Smith EM: Human leukocyte interferon (HulFN-α): Potent endorphin-like opioid activity. Biochem Biophys ResCommun 1981; 101:472-478.
16. Birmanns B, Saphier D, Abramsky O: α-Inter-feron modifies cortical EEC activity: dosc-depcndcnce and antagonism by naloxone. J Neurol Sci 1990;100:22-26.
17. Jomvall H, Persson M, Ekman R: Structural comparisons of leukocyte interferon and proopiomelanocortin correlated with immunological similarities. FEBS Lett 1982:137:153-156.
18. Gisslinger H, Svoboda T, Clodi M, Gilly B, Ludwig H, Havelec L, Luger A: Interferon-a stimulates the hypolhalamic-pituitary-adrenal axis in vivo and in vitro. Neuroendocrinology 1993;57:489-495.
19. Okada F, Honma M, Ui M: Plasma guanosine 3'.5'-monophosphate responses to methachol-ine and epinephrine in humans. J Clin Endocrinol Metab 1982;54:645-647.
20. Kagaya A, Motohashi N, Kugaya A, Yantaji T, Havashi T, Okamolo Y, Shinno H, Takebaya-shi M, Uchitomi Y, Yamawaki S: Cyclic GMP generation mediated by 5-HT-2 receptors via nitric oxide-dependent pathway and its effect on the desensitization of 5-HT-2 receptors in C6 glioma cells. J Neural Transm Gen Sect 1995:100:27-38.
21. Meitzer HY, Umberkoman-Wiita B, Robertson A, Tricou BJ, Lowy M, Perline R: Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. 1. Enhanced response in depression and mania. Arch Gen Psychiatry 1984;41:366-374.
22. Mikuni M, Kagava A, Takahashi K, Meltzer HY: Serotonin but not norepinephrine-induced calcium mobilization is enhanced in platelets of affective disorders. Psychopharmacology 1992;106:311-314.
23. Okamoto Y, Kagaya A, Shinno H, Motohashi N, Yamawaki S: Serotonin-induced platelet calcium mobilization is enhanced in mania. Life Sci 1995;56:327-332.
24. Yamawaki S, Kagaya A, Hayakawa H, Okamoto Y, Kugaya A, Takcbayashi M, Muraoka M. Uchitomi Y: Pathophysiology of affective disorders: Serotonin receptor function and intracellular calcium signaling; in Takada A. Curzon G (eds): Serotonin in the Central Nervous System and Periphery. Amsterdam. Elsevier, 1995, pp 31-39.